Gain-of-function mutations of the tyrosine kinase (TK) receptor encoding gene FLT3 occur in approximately 30% of AML patients, and result in constitutive TK activity and, in turn, increasing growth and survival of leukemia blasts [2]. The gene discussed is FLT3; the disease is acute myeloid leukemia.